Literature DB >> 24156322

Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.

Akiko Kukita1, Toshio Kukita.   

Abstract

It is known that there are close relationships between bone destruction and tumor growth in bone metastasis. RANKL is a central factor in bone metastasis, inducing osteoclastogenesis mediated by its receptor RANK. Recent reports demonstrate that RANKL has important roles in organogenesis stimulating proliferation and differentiation of epithelial and stroma cells. RANKL is induced not only by cytokines and hormones but also by UV-irradiation, inflammation and carcinogens. Expression of RANK and RANKL is found in several human cancer cell lines, and RANK signaling stimulates proliferation, migration and epithelial-mesenchymal transition of cancer cells, which may be involved in metastasis via an autocrine/paracrine mechanism. RANKL regulates the number of Tregs that produce RANKL, which may affect cancer metastasis. In this review we discuss the multifunctional roles of RANKL/RANK in osteoclastogenesis, organogenesis, and the metastasis and tumorigenesis of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24156322     DOI: 10.2217/fon.13.115

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

1.  Langerhans cell precursors acquire RANK/CD265 in prenatal human skin.

Authors:  Alice Schöppl; Albert Botta; Marion Prior; Johnnie Akgün; Christopher Schuster; Adelheid Elbe-Bürger
Journal:  Acta Histochem       Date:  2015-02-24       Impact factor: 2.479

2.  Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.

Authors:  Stéphanie A Demoulin; Joan Somja; Anaëlle Duray; Samuel Guénin; Patrick Roncarati; Philippe O Delvenne; Michael F Herfs; Pascale M Hubert
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

3.  RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?

Authors:  Carlo Resteghini; Salvatore Alfieri; Pasquale Quattrone; Francesca Dominoni; Giovanna Garzone; Ester Orlandi; Laura Locati; Cristiana Bergamini; Donata Galbiati; Nicola Alessandro Iacovelli; Carlo Fallai; Lisa Licitra; Paolo Bossi
Journal:  Oncotarget       Date:  2017-10-16

4.  Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?

Authors:  Francesca Punzo; Chiara Tortora; Maura Argenziano; Daniela Di Pinto; Elvira Pota; Martina Di Martino; Alessandra Di Paola; Francesca Rossi
Journal:  Oncotarget       Date:  2020-07-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.